A Randomized, Controlled Study Evaluating Effects of Saccharomyces boulardii in Adult Patients with Asthma

Abstract

Objective

To determine the potential benefit of adding Saccharomyces boulardii (S. boulardii) probiotic supplementation to conventional treatments in asthmatic patients.

Materials and methods

In this randomized, double-blinded, and placebo-controlled trial 50 asthmatic patients were enrolled. The eligible subjects received either S. boulardii (N=25) or placebo (N=25) added to conventional treatments for three months. Spirometry parameters (FEV1, FVC, FEV1/FVC, and FEF 25–75%) and blood test parameters (CBC, eosinophil percentage, IgE, IL-5, ESR and CRP) were measured and compared at baseline and after treatment completion.

Results

The mean age was 39.22±12.55 years. As compared to baseline values, a significant improvement was noted in FEV1 in patients who received S. boulardii (p=0.026). Although the changes in FEV1, FVC, FEV1/FVC, and FEF 25–75% were comparable between the study groups, the differences were not statistically significant (p ˃ 0.05). In addition, patients who received probiotic showed lower levels of IL-5 and IgE in comparison with patients who received placebo.

Conclusion

Our findings showed that the addition of S. boulardii to conventional treatments partially improved the pulmonary function and was associated with reductions in IgE and IL-5 levels.

Keywords

asthma - probiotics - saccharomyces boulardii - spirometry

Publication History

Received: 02 July 2024

Accepted: 15 March 2025

Article published online:
14 April 2025

• References

• 1 GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. EClinicalMedicine 2023; 59: 101936
• 2 Carr TF, Zeki AA, Kraft M. Eosinophilic and Noneosinophilic Asthma. Am J Respir Crit Care Med 2018; 197: 22-37
• 3 Ray A, Kolls JK. Neutrophilic Inflammation in Asthma and Association with Disease Severity. Trends Immunol 2017; 38: 942-54
• 4 Fijan S, Frauwallner A, Varga L. et al. Health professionals’ knowledge of probiotics: an international survey. International journal of environmental research and public health 2019; 16: 3128
• 5 Misra S, Pandey P, Mishra HN. Novel approaches for co-encapsulation of probiotic bacteria with bioactive compounds, their health benefits and functional food product development: A review. Trends in Food Science & Technology 2021; 109: 340-351
• 6 Sadrifar S, Abbasi-Dokht T, Forouzandeh S. et al. Immunomodulatory effects of probiotic supplementation in patients with asthma: a randomized, double-blind, placebo-controlled trial. Allergy, Asthma & Clinical Immunology 2023; 19: 1-10
• 7 van den Akker CH, Van Goudoever JB, Shamir R. et al. Probiotics and preterm infants: a position paper by the European Society for paediatric gastroenterology hepatology and nutrition Committee on nutrition and the European Society for paediatric gastroenterology hepatology and nutrition Working group for probiotics and prebiotics. Journal of pediatric gastroenterology and nutrition 2020; 70: 664-80
• 8 Sen M. Role of probiotics in health and disease–A review. International Journal of Advancement in Life Sciences Research 2019; 1-11
• 9 Diez-Gutiérrez L, San Vicente L, Barrón LJR. et al. Gamma-aminobutyric acid and probiotics: Multiple health benefits and their future in the global functional food and nutraceuticals market. Journal of Functional Foods 2020; 64: 103669
• 10 Bisyuk Y, Litus O, Boyko N. et al. Combinations of Probiotic Bacteria (Lactobacillus helveticus, Bifidobacterium longum, Lactobacillus rhamnosus, Sacchammyces boulardii) Restores the Skin Microbiome in Atopic Dermatitis. Journal of Allergy and Clinical Immunology 2023; 151: AB148
• 11 Kaźmierczak-Siedlecka K, Ruszkowski J, Fic M. et al. Saccharomyces boulardii CNCM I-745: A non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases. Current microbiology 2020; 77: 1987-96
• 12 Zhang P, Chen X, Chen B. et al. Study on asthmatic children serum cytokine levels and saccharomyces boulardii intervention. Chinese Journal of Clinical Pharmacology and Therapeutics 2017; 22: 332
• 13 Gao X, Wang Y, Shi L. et al. Effect and safety of Saccharomyces boulardii for neonatal necrotizing enterocolitis in pre-term infants: a systematic review and meta-analysis. Journal of Tropical Pediatrics 2021; 67: fmaa022
• 14 Szajewska H, Kołodziej M, Zalewski BM. Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update. Alimentary pharmacology & therapeutics 2020; 51: 678-88
• 15 Zhou BG, Chen LX, Li B. et al. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter 2019; 24: e12651
• 16 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2019
• 17 World Health Organization. World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action. 2005. World Health Organization;
• 18 Du X, Wang L, Wu S. et al. Efficacy of probiotic supplementary therapy for asthma, allergic rhinitis, and wheeze: a meta-analysis of randomized controlled trials. Allergy Asthma Proc 2019; 40: 250-60
• 19 Wei X, Jiang P, Liu J. et al. Association between probiotic supplementation and asthma incidence in infants: a meta-analysis of randomized controlled trials. J Asthma 2020; 57: 167-78
• 20 Lin J, Zhang Y, He C. et al. Probiotics supplementation in children with asthma: A systematic review and meta-analysis. J Paediatr Child Health 2018; 54: 953-61
• 21 Karen M, Yuksel O, Akyürek N. et al. Probiotic agent Saccharomyces boulardii reduces the incidence of lung injury in acute necrotizing pancreatitis induced rats. Journal of Surgical Research 2010; 160: 139-144
• 22 Li J, Gao PF, Xu YX. et al. Probiotic Saccharomyces boulardii attenuates cardiopulmonary bypass-induced acute lung injury by inhibiting ferroptosis. American Journal of Translational Research 2022; 14: 5003
• 23 Sudo N, Yu XN, Aiba Y. et al. An oral introduction of intestinal bacteria prevents the development of a long-term Th2-skewed immunological memory induced by neonatal antibiotic treatment in mice. Clinical & Experimental Allergy 2002; 32: 1112-1116
• 24 Chen YS, Lin YL, Jan RL. et al. Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis. Pediatric pulmonology 2010; 45: 1111-1120
• 25 Pochard P, Gosset P, Grangette C. et al. Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients. Journal of Allergy and Clinical Immunology 2002; 110: 617-623
• 26 Prescott SL, Dunstan JA, Hale J. et al. Clinical effects of probiotics are associated with increased interferon-γ responses in very young children with atopic dermatitis. Clinical & Experimental Allergy 2005; 35: 1557-1564
• 27 Giovannini M, Agostoni C, Riva E. et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatric research 2007; 62: 215-220
• 28 Rose MA, Stieglitz F, Köksal A. et al. Efficacy of probiotic Lactobacillus GG on allergic sensitization and asthma in infants at risk. Clinical & Experimental Allergy 2010; 40: 1398-1405
• 29 Wheeler JG, Shema SJ, Bogle ML. et al. Immune and clinical impact of Lactobacillus acidophilus on asthma. Annals of Allergy, Asthma & Immunology 1997; 79: 229-233